Table 2.
Clinical outcomes with a reduced dose of a direct oral anticoagulant according to the concordance of the drug indication between the Cockcroft-Gault formula and other formulae.
| Event Rate (%/year) | Adjusted HR (95% CI) * |
P ** | ||
|---|---|---|---|---|
| DOAC | Warfarin | |||
| Thromboembolism | ||||
| Concordant (on-label by CG and on-label by CKD-EPI) vs. Warfarin | 1.95 | 1.35 | 0.75 (0.34–1.63) | 0.465 |
| Discordant (on-label by CG and off-label by CKD-EPI) vs. Warfarin | 1.90 | 1.35 | 0.80 (0.19–3.41) | 0.759 |
| Discordant vs. Concordant (CG and CKD-EPI) | 1.39 (0.29–6.69) | 0.680 | ||
| Concordant (on-label by CG and on-label by MDRD) vs. Warfarin | 1.97 | 1.35 | 0.76 (0.35–1.65) | 0.482 |
| Discordant (on-label by CG and off-label by MDRD) vs. Warfarin | 1.83 | 1.35 | 0.75 (0.18–3.23) | 0.704 |
| Discordant vs. Concordant (CG and MDRD) | 1.21 (0.25–5.82) | 0.811 | ||
| Major bleeding | ||||
| Concordant (on-label by CG and on-label by CKD-EPI) vs. Warfarin | 1.51 | 2.14 | 0.36 (0.16–0.81) | 0.014 |
| Discordant (on-label by CG and off-label by CKD-EPI) vs. Warfarin | 0.00 | 2.14 | 0.59 (0.16–2.18) | 0.432† |
| Discordant vs. Concordant (CG and CKD-EPI) | 0.82 (0.08–7.94) | 0.862† | ||
| Concordant (on-label by CG and on-label by MDRD) vs. Warfarin | 1.53 | 2.14 | 0.36 (0.16–0.82) | 0.015 |
| Discordant (on-label by CG and off-label by MDRD) vs. Warfarin | 0.00 | 2.14 | 0.59 (0.17–2.13) | 0.423† |
| Discordant vs. Concordant (CG and MDRD) | 0.67 (0.07–6.35) | 0.730† | ||
* Adjusted for age, sex, body weight, comorbidities (congestive heart failure, hypertension, diabetes mellitus, prior thromboembolism), concomitant use of an antiplatelet drug, and serum creatinine. ** P-value required for statistical significance was <0.017 (with the Bonferroni correction). † Firth’s bias reduction method used because of no event.